Premium
A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug
Author(s) -
Wallace John L.,
Nagy Peter,
Feener Troy D.,
Allain Thibault,
Ditrói Tamás,
Vaughan David J.,
Muscara Marcelo N.,
Nucci Gilberto,
Buret Andre G.
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14641
Subject(s) - naproxen , medicine , analgesic , gastroenterology , drug , nausea , toxicity , antipyretic , incidence (geometry) , pharmacology , pathology , alternative medicine , physics , optics
ATB-346 is a hydrogen sulfide (H 2 S)-releasing anti-inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti-inflammatory effects. In humans, ATB-346 (250 mg once daily) was found to inhibit COX to the same extent as naproxen (550 mg twice daily).